ARF1

ARF1 Full Name

ADP-ribosylation factor 1

ARF1 Introduction

ARF1 (ADP ribosylation factor 1) is a member of the ARF family of small GTPases, which belong to the Ras superfamily. The gene is located on chromosome 1q42.13 and encodes a protein of 181 amino acids with a molecular weight of approximately 21 kDa. ARF1 is ubiquitously expressed in all human tissues and is one of the most evolutionarily conserved small GTPases, with orthologs found in all eukaryotes from yeast to humans. ARF1 functions as a master regulator of membrane trafficking, particularly at the Golgi apparatus, where it controls the formation of COPI (coat protein complex I)-coated vesicles that mediate retrograde transport from the Golgi to the endoplasmic reticulum (ER) and intra-Golgi transport. ARF1 cycles between an inactive GDP-bound form (cytosolic) and an active GTP-bound form (membrane-associated). Guanine nucleotide exchange factors (GEFs) promote the exchange of GDP for GTP, activating ARF1 and targeting it to membranes, while GTPase-activating proteins (GAPs) stimulate GTP hydrolysis, inactivating ARF1 and releasing it from membranes. In its active form, ARF1 recruits coat proteins, including coatomer (COPI), to Golgi membranes, induces membrane curvature, and facilitates vesicle budding and cargo selection. Beyond its canonical role in COPI vesicle formation, ARF1 regulates endosomal recycling, lipid droplet dynamics, the unfolded protein response (UPR), and cell adhesion, positioning it as a central node in cellular homeostasis.

Figure 1. Schematic structure of ARF1.

Gene Structure and Protein Architecture
The human ARF1 gene spans approximately 4.5 kb and contains 6 exons, with several pseudogenes located on other chromosomes. The full-length protein consists of 181 amino acids and contains the characteristic structural features of ARF family small GTPases. Unlike most Ras family GTPases that are C-terminally prenylated, ARF1 is myristoylated at its N-terminal glycine residue (Gly-2), a co-translational modification that is essential for its membrane association and function. The N-terminal region (amino acids 1-17) forms an amphipathic helix that inserts into the lipid bilayer upon GTP binding, contributing to membrane anchoring. The protein contains the conserved GTP-binding motifs including the P-loop (GXXXXGKS, amino acids 24-31) that coordinates the phosphate groups of GTP, the switch I region (amino acids 40-50) and switch II region (amino acids 70-80) that undergo conformational changes upon GTP binding and hydrolysis, and the G4 motif (NKXD) and G5 motif (SAK/T) that contribute to guanine nucleotide specificity. Key residues for GTP hydrolysis include Gln-71 (which coordinates the nucleophilic water molecule) and Arg-149 (which stabilizes the transition state). ARF1 also contains an interswitch region that transmits conformational changes between the nucleotide-binding site and the N-terminal helix. The three-dimensional structure of ARF1-GTP reveals a globular GTPase domain with a unique N-terminal extension that folds back onto the core domain in the GDP-bound form but extends outward in the GTP-bound form.

Pathophysiological and Clinical Significance of ARF1
Abnormal overexpression, sustained hyperactivation, or functional dysregulation of ARF1 profoundly impacts the initiation and progression of multiple human diseases, possessing important clinical research and translational therapeutic value. In metabolic and organ injury diseases, aberrant ARF1 activation disrupts Golgi structural stability and intracellular protein transport balance, leading to cellular metabolic disorder, endoplasmic reticulum stress, and apoptotic cell death, which contributes to hepatic steatosis, renal tubular injury, and neurodegenerative lesions. In chronic inflammatory diseases, excessive ARF1 activity promotes abnormal inflammatory cytokine secretion and immune cell vesicle trafficking dysfunction, amplifying persistent inflammatory infiltration and tissue damage. In human malignancies, ARF1 is frequently significantly upregulated in lung cancer, breast cancer, gastric cancer, hepatocellular carcinoma, and other solid tumors. Overactivated ARF1 remodels tumor cell membrane trafficking and cytoskeletal dynamics, effectively promoting tumor cell proliferation, epithelial-mesenchymal transition, invasion, and distant metastasis, while enhancing tumor angiogenesis and chemotherapy resistance. Clinically, elevated ARF1 expression levels are closely correlated with advanced tumor grade, increased metastasis risk, and poor patient prognosis, making ARF1 a promising prognostic biomarker and targeted therapeutic candidate for multiple human diseases.

Alternate Names for ARF1

ARF1; ADP-ribosylation factor 1;